Predictors and Patterns of Metastatic Candidozyma auris Infection, Spain, 2016–2024
Abstract
Metastatic infection after Candidozyma auris candidemia remains poorly characterized. We retrospectively studied patients with C. auris candidemia at a tertiary hospital in Spain during 2016–2024. Of 108 patients, 24 (22.2%) experienced metastatic infections; endocarditis was most frequent (7.4%), followed by osteoarticular infection, meningitis, and hepatosplenic infection (3.7% each). In multivariable Fine–Gray regression, a cardiac device or prosthetic valve was independently associated with metastatic infection (subdistribution hazard ratio [HR] 2.89 [95% CI 1.21–6.91]), although that association was attenuated in a sensitivity analysis restricted to echocardiographed patients. Persistent candidemia showed a higher, nonsignificant risk for metastatic infection in the day-5 landmark analysis (subdistribution HR 2.67 [95% CI 0.86–8.32]). Metastatic infection was associated with increased deaths in time-dependent analyses at 60 days (adjusted HR 2.21 [95% CI 1.04–4.67]) and 90 days (adjusted HR 2.26 [95% CI 1.09–4.67]). Our findings support echocardiography in patients with intracardiac devices.
Related
- Candidozyma auris (Candida auris) as a harbinger of novel fungal pathogens
- Candidozyma auris (formerly Candida auris): A P6 medicine framework integrating genomics, surveillance and the prevention of multidrug-resistant fungal threats.
- Fungicidal effects of eight disinfectants against resistant Candidozyma auris (formerly Candida auris), Aspergillus fumigatus, and Trichophyton indotineae
- Antifungal activity of the nucleoside mimetic 5-fluorouridine against Candidozyma auris and Candida species
- Whole-genome characterization of Candidozyma auris isolates from a Korean tertiary care centre: clade II predominance, partly unexplained fluconazole resistance and a clade I isolate
BibTeX
@article{suarezurquiza2026predictors,
title = {{Predictors and Patterns of Metastatic Candidozyma auris Infection, Spain, 2016–2024}},
author = {Pedro Suarez-Urquiza and Alba Ruiz-Gaitán and Eva Calabuig and María Tasias and Víctor García Bustos and Ignacio Moreno and María Ángeles Ferre and Ana María Moret and Juan Frasquet and Patricio Favier and Javier Pemán and Maria Jesus Castaño-Aroca and Paula Muñoz Brell and Mónica Gordon and Maria Dolores Gomez-Ruiz and Miguel Salavert-Lleti},
journal = {Emerging Infectious Diseases},
year = {2026},
month = oct,
doi = {10.3201/eid3211.260984},
url = {https://doi.org/10.3201/eid3211.260984},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Predictors and Patterns of Metastatic Candidozyma auris Infection, Spain, 2016–2024
AU - Pedro Suarez-Urquiza
AU - Alba Ruiz-Gaitán
AU - Eva Calabuig
AU - María Tasias
AU - Víctor García Bustos
AU - Ignacio Moreno
AU - María Ángeles Ferre
AU - Ana María Moret
AU - Juan Frasquet
AU - Patricio Favier
AU - Javier Pemán
AU - Maria Jesus Castaño-Aroca
AU - Paula Muñoz Brell
AU - Mónica Gordon
AU - Maria Dolores Gomez-Ruiz
AU - Miguel Salavert-Lleti
PY - 2026
DA - 2026/10/30
JO - Emerging Infectious Diseases
DO - 10.3201/eid3211.260984
UR - https://doi.org/10.3201/eid3211.260984
AB - Metastatic infection after Candidozyma auris candidemia remains poorly characterized. We retrospectively studied patients with C. auris candidemia at a tertiary hospital in Spain during 2016–2024. Of 108 patients, 24 (22.2%) experienced metastatic infections; endocarditis was most frequent (7.4%), followed by osteoarticular infection, meningitis, and hepatosplenic infection (3.7% each). In multivariable Fine–Gray regression, a cardiac device or prosthetic valve was independently associated with metastatic infection (subdistribution hazard ratio [HR] 2.89 [95% CI 1.21–6.91]), although that association was attenuated in a sensitivity analysis restricted to echocardiographed patients. Persistent candidemia showed a higher, nonsignificant risk for metastatic infection in the day-5 landmark analysis (subdistribution HR 2.67 [95% CI 0.86–8.32]). Metastatic infection was associated with increased deaths in time-dependent analyses at 60 days (adjusted HR 2.21 [95% CI 1.04–4.67]) and 90 days (adjusted HR 2.26 [95% CI 1.09–4.67]). Our findings support echocardiography in patients with intracardiac devices.
SN - 1080-6040
SN - 1080-6059
ER -